Equities

Amicus Therapeutics Inc

Amicus Therapeutics Inc

Actions
  • Price (USD)10.98
  • Today's Change0.051 / 0.46%
  • Shares traded1.45k
  • 1 Year change-3.40%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 19:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments286294482
Total Receivables, Net886653
Total Inventory602427
Prepaid expenses504035
Other current assets, total------
Total current assets483424597
Property, plant & equipment, net586063
Goodwill, net198198198
Intangibles, net202323
Long term investments------
Note receivable - long term------
Other long term assets191924
Total assets778724905
LIABILITIES
Accounts payable151522
Accrued expenses1308995
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total233529
Total current liabilities168139146
Total long term debt388392389
Total debt388392389
Deferred income tax--4.944.93
Minority interest------
Other liabilities, total626558
Total liabilities618601598
SHAREHOLDERS EQUITY
Common stock2.922.822.81
Additional paid-in capital2,8362,6652,595
Retained earnings (accumulated deficit)(2684)(2532)(2296)
Treasury stock - common------
Unrealized gain (loss)(0.19)(0.12)(0.27)
Other equity, total5.43(12)5.25
Total equity160123307
Total liabilities & shareholders' equity778724905
Total common shares outstanding294281279
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.